Treatment of locally aggressive benign bone tumors by means of extended intralesional curettage without chemical adjuvants

SAGE Open Med. 2022 Apr 22;10:20503121221094199. doi: 10.1177/20503121221094199. eCollection 2022.

Abstract

Objectives: The aim of this study is to present the clinical, oncological, and functional results of locally aggressive benign bone tumors treated with extended intralesional curettage without the use of adjuvant in a tertiary orthopedic oncology center.

Method: A total of 172 patients treated with surgical curettage and high-speed burrs for the diagnosis of aneurysmal bone cyst, giant cell tumor, osteoblastoma, chondroblastoma, and chondromyxoid fibroma were included in the study. Demographic, radiological, and clinical data of the patients were analyzed.

Results: One-hundred seventy two patients (101 (59%) female and 71 (41%) male) with a mean age of 23 years (6-84). The mean follow-up period was 48 months (18-108). In the study, a total of 8 (4.6%) patients had postoperative complications, 17 (9.9%) patients had recurrence in the postoperative period. Diameter greater than 5 cm was found to be a risk factor for recurrence (p < 0.004). The probability of developing complications was found to be significantly higher in patients with recurrence (p < 0.001). There was no significant relationship between recurrence and age, tumor type, and tumor stage.

Conclusion: Successful treatment results can be obtained with extended surgical curettage, high-speed burr, and cauterization without the use of chemical adjuvants in locally aggressive bone tumors.

Keywords: Treatment; bone tumor; curettage; local aggressive; recurrence.